Retatrutide Reconstitution Guide: Mixing, Concentration Math and Storage
How to reconstitute lyophilized retatrutide correctly. Vial-by-water concentration tables, insulin syringe conversions for every trial dose, storage windows, and worked math for a full escalation on one vial.
Table of Contents
- 1.Why Retatrutide Ships as a Lyophilized Powder
- 2.Supplies You Will See Referenced
- 3.Bacteriostatic Water Versus Sterile Water
- 4.Step by Step: The Mixing Procedure
- 5.The Concentration Math
- 6.Concentration Reference Table
- 7.Dose-to-Units Reference Table
- 8.The Information Gain: Picking a Water Volume So Doses Land on Clean Marks
- 9.Worked Example: A Full Escalation on One 10 mg Vial
- 10.Storage: Powder Versus Reconstituted Solution
- 11.How This Fits the Broader Retatrutide Picture
- 12.A Note on the "GLP-3" and "Triple G" Nicknames
- 13.Frequently Asked Questions
- 14.Key Research Citations
Retatrutide (LY3437943) ships as a lyophilized powder because the peptide is not stable in solution for long, and reconstitution is the step where most avoidable errors happen. This guide covers what the powder is, the supplies involved, a careful mixing procedure, the concentration math, and a decision framework for choosing a water volume so that every dose across a full escalation lands on a clean insulin-syringe mark. Retatrutide is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors (Molecular Metabolism, 2022) and is not approved by the FDA for human use.
This article is for research and educational purposes only. Retatrutide is an investigational compound with no approved human indication. Nothing here is medical advice, a dosing recommendation, or an instruction to administer any substance.
Why Retatrutide Ships as a Lyophilized Powder
Lyophilization (freeze-drying) removes water from the peptide under vacuum, leaving a dry cake or pellet at the bottom of the vial. Peptides in the incretin class degrade through hydrolysis, deamidation, and aggregation when held in aqueous solution, and those reactions accelerate with time and temperature. Shipping and storing the compound as a dry solid slows that chemistry to a near halt, which is why research material arrives as a powder rather than a ready-to-use liquid.
Reconstitution is simply the act of adding a measured volume of water back to that powder to create a solution of known concentration. Because retatrutide has a terminal half-life of roughly 6 days and is dosed once weekly, a single vial is used across multiple weeks, so the solution has to remain stable for the life of the vial. That is the single most important reason the choice of water matters.
The core idea to internalize before touching anything: the powder amount is fixed, but you control the final concentration by choosing how much water you add. More water gives a weaker, higher-volume solution; less water gives a stronger, lower-volume solution. Neither changes the total milligrams in the vial. Everything downstream, including how many syringe units each dose requires, flows from that one decision. If you would rather skip the arithmetic entirely, the reconstitution calculator does it for you.
Supplies You Will See Referenced
- The sealed retatrutide vial (commonly labeled 5 mg, 10 mg, 15 mg, 20 mg, or 30 mg of peptide)
- Bacteriostatic water (BAC water), typically a multi-dose vial containing 0.9% benzyl alcohol
- U-100 insulin syringes (100 units per mL) for measuring and drawing doses
- A larger syringe or the same insulin syringe for transferring water into the powder vial
- Alcohol swabs (70% isopropyl) for the rubber stoppers
- A clean, flat work surface and a way to store the vial cold and dark
Bacteriostatic Water Versus Sterile Water
This is the distinction that trips up most people, and it directly determines how long a reconstituted vial lasts.
| Property | Bacteriostatic water | Sterile water |
|---|---|---|
| Additive | 0.9% benzyl alcohol (bacteriostatic preservative) | None |
| Suppresses microbial growth | Yes | No |
| Suitable for multi-dose vials | Yes, this is its purpose | No, single use only |
| Typical reconstituted window | 28 to 56 days refrigerated | Effectively single-use; no preservative protection |
| Why it matters here | Retatrutide is dosed weekly, so a vial is punctured many times | Every re-entry risks introducing microbes with nothing to suppress them |
Because retatrutide is a once-weekly compound, a reconstituted vial is punctured repeatedly over weeks. Every needle entry is an opportunity to introduce microorganisms. The benzyl alcohol in BAC water is bacteriostatic, meaning it inhibits bacterial growth, which is what makes a multi-week, multi-dose vial workable. Sterile water contains no preservative, so a vial reconstituted with it has no protection against contamination between draws. For a multi-dose peptide, BAC water is the water of record. This is also why the commonly cited stability window (28 to 56 days) is tied specifically to BAC-water-preserved solution kept cold.
Step by Step: The Mixing Procedure
The goal of the technique is to protect a fragile peptide from mechanical stress while getting it fully into solution.
- Let the vial reach room temperature. If the powder vial or BAC water was refrigerated, allow both to warm to room temperature first. Adding cold water to cold powder slows dissolution and can cause condensation.
- Swab both stoppers. Wipe the rubber stopper of the peptide vial and the BAC water vial with a fresh alcohol swab and let them air dry.
- Draw your chosen water volume. Pull the pre-decided amount of BAC water (see the tables below) into a syringe.
- Inject slowly down the vial wall. Insert the needle at an angle and let the water run down the inside glass wall of the vial rather than blasting it directly onto the powder cake. A slow, gentle stream reduces foaming and shear stress on the peptide.
- Do not shake. Shaking introduces air, creates foam, and can denature or aggregate the peptide, degrading potency.
- Swirl gently. Roll or swirl the vial slowly in your hand. Set it down and give it time.
- Wait for full dissolution. The solution should turn completely clear with no visible particles, cloudiness, or floating cake fragments. This can take several minutes. If anything remains undissolved, continue gentle swirling and waiting, never shaking.
A properly reconstituted vial holds a clear, colorless solution. Cloudiness, discoloration, or persistent particulate is a signal that something is wrong with the material or the technique. For a fuller walkthrough of handling and what can go wrong, the side effects and handling guide covers adjacent ground.
The Concentration Math
Three formulas do all the work. They are simple, and understanding them means you never depend on a chart that does not list your exact vial size.
- Concentration (mg/mL) = total mg in vial / mL of BAC water added
- Dose volume (mL) = target dose (mg) / concentration (mg/mL)
- Syringe units on a U-100 = dose volume (mL) x 100
The third line is the one people forget. An insulin syringe labeled U-100 has 100 units per milliliter, so 0.10 mL is 10 units, 0.25 mL is 25 units, and 0.50 mL is 50 units. Every dose you draw is really just a volume, and units are simply that volume multiplied by 100.
Worked example: a 10 mg vial reconstituted with 2 mL of BAC water gives a concentration of 10 / 2 = 5 mg/mL. A 2 mg dose is 2 / 5 = 0.4 mL, which is 0.4 x 100 = 40 units. A 4 mg dose is 4 / 5 = 0.8 mL, which is 80 units. The dosing calculator runs these three lines instantly for any combination you enter.
Concentration Reference Table
The table below crosses every common vial size with common BAC water volumes to give the resulting concentration in mg/mL. Concentration is the master number; every dose volume derives from it.
| Vial size | 1 mL water | 2 mL water | 3 mL water | 5 mL water |
|---|---|---|---|---|
| 5 mg | 5.0 mg/mL | 2.5 mg/mL | 1.67 mg/mL | 1.0 mg/mL |
| 10 mg | 10.0 mg/mL | 5.0 mg/mL | 3.33 mg/mL | 2.0 mg/mL |
| 15 mg | 15.0 mg/mL | 7.5 mg/mL | 5.0 mg/mL | 3.0 mg/mL |
| 20 mg | 20.0 mg/mL | 10.0 mg/mL | 6.67 mg/mL | 4.0 mg/mL |
| 30 mg | 30.0 mg/mL | 15.0 mg/mL | 10.0 mg/mL | 6.0 mg/mL |
Dose-to-Units Reference Table
This is the table most people actually want: for a given concentration, how many U-100 syringe units correspond to each of the doses studied in the retatrutide Phase 2 program (1, 2, 4, 6, 8, and 12 mg). Values are rounded to the nearest whole unit. A blank means the draw exceeds 100 units (1 mL), which is more than a single insulin syringe holds and signals the concentration is too dilute for that dose.
| Concentration | 1 mg | 2 mg | 4 mg | 6 mg | 8 mg | 12 mg |
|---|---|---|---|---|---|---|
| 1.0 mg/mL | 100 u | (over 1 mL) | (over 1 mL) | (over 1 mL) | (over 1 mL) | (over 1 mL) |
| 2.0 mg/mL | 50 u | 100 u | (over 1 mL) | (over 1 mL) | (over 1 mL) | (over 1 mL) |
| 2.5 mg/mL | 40 u | 80 u | (over 1 mL) | (over 1 mL) | (over 1 mL) | (over 1 mL) |
| 3.0 mg/mL | 33 u | 67 u | (over 1 mL) | (over 1 mL) | (over 1 mL) | (over 1 mL) |
| 5.0 mg/mL | 20 u | 40 u | 80 u | (over 1 mL) | (over 1 mL) | (over 1 mL) |
| 6.0 mg/mL | 17 u | 33 u | 67 u | 100 u | (over 1 mL) | (over 1 mL) |
| 7.5 mg/mL | 13 u | 27 u | 53 u | 80 u | (over 1 mL) | (over 1 mL) |
| 10.0 mg/mL | 10 u | 20 u | 40 u | 60 u | 80 u | (over 1 mL) |
| 15.0 mg/mL | 7 u | 13 u | 27 u | 40 u | 53 u | 80 u |
| 20.0 mg/mL | 5 u | 10 u | 20 u | 30 u | 40 u | 60 u |
| 30.0 mg/mL | 3 u | 7 u | 13 u | 20 u | 27 u | 40 u |
Two patterns fall out of this table. First, low concentrations run out of syringe room fast: at 1.0 mg/mL you cannot even fit a 2 mg dose in one insulin syringe. Second, high concentrations make small doses hard to measure accurately: at 30 mg/mL, a 1 mg dose is just 3 units, where a one-unit error is a 33% dosing error. The sweet spot for measurement precision sits in the middle, and that is exactly where the escalation problem lives.
The Information Gain: Picking a Water Volume So Doses Land on Clean Marks
Here is the practical problem that generic guides skip. The retatrutide Phase 2 obesity trial (New England Journal of Medicine, 2023) escalated participants through 1, 4, 8, and 12 mg weekly. If someone reconstitutes a vial without planning for the whole escalation, they end up with doses that fall between syringe gradations, forcing them to eyeball fractional units. That is where measurement error creeps in.
The fix is to reverse the logic: instead of picking a water volume and accepting whatever units result, pick the water volume that makes your intended doses land on round, easy-to-read units. Insulin syringes are marked in single units, and doses that land on multiples of 5 or 10 units are far easier to draw accurately than doses landing on, say, 27 units.
The decision rule: choose the water volume that turns your most-used dose into a clean multiple of 5 or 10 units. Concentration equals vial mg divided by water mL, and units equal dose divided by concentration times 100, so the water volume that produces a clean dose is fully predictable.
| Goal | Vial | Water volume | Concentration | Resulting units for the target dose |
|---|---|---|---|---|
| Clean 2 mg dose | 10 mg | 2 mL | 5.0 mg/mL | 2 mg = 40 u |
| Clean 4 mg dose | 10 mg | 2.5 mL | 4.0 mg/mL | 4 mg = 100 u (max) |
| Clean 8 mg dose | 20 mg | 2.5 mL | 8.0 mg/mL | 8 mg = 100 u (max) |
| Clean 12 mg dose | 30 mg | 3 mL | 10.0 mg/mL | 12 mg = (over 1 mL, must split) |
| Balanced whole-escalation | 10 mg | 1 mL | 10.0 mg/mL | 1 mg = 10 u, 4 mg = 40 u, 8 mg = 80 u |
Notice the tension in the middle rows: optimizing a single dose to land on exactly 100 units leaves no headroom, and a 12 mg dose at any reasonable concentration either fills or exceeds a single syringe. That is why the balanced approach usually wins. The calculator lets you test water volumes against your full dose ladder before you commit.
Worked Example: A Full Escalation on One 10 mg Vial
Suppose the plan is to escalate 1 mg, then 4 mg, then 8 mg on a single 10 mg vial reconstituted with 1 mL of BAC water. Concentration is 10 / 1 = 10 mg/mL.
- 1 mg dose: 1 / 10 = 0.10 mL = 10 units. Clean.
- 4 mg dose: 4 / 10 = 0.40 mL = 40 units. Clean.
- 8 mg dose: 8 / 10 = 0.80 mL = 80 units. Clean.
Every dose lands on a multiple of 10 units, which is about as easy to read as an insulin syringe gets. This is why 1 mL into a 10 mg vial is such a common choice: it makes the escalation doses fall on tidy marks.
Now watch what happens as the vial empties. That single 10 mg vial holds exactly 10 mg. One 1 mg dose plus one 4 mg dose plus one 8 mg dose sums to 13 mg, which is more than the vial contains. So a 10 mg vial does not carry a full escalation on its own; it carries roughly a 1 mg week plus a 4 mg week with a little left over, or a single 8 mg week with 2 mg remaining. The remaining 2 mg is not enough for the next scheduled 8 mg dose, and that leftover is where waste and improvisation happen.
When to Re-Dilute or Re-Plan
- When the remaining volume cannot cover the next dose. If 0.20 mL (20 units, 2 mg) is left and the next dose is 8 mg, that vial is done; open a fresh vial rather than combining partial vials.
- When you move up a dose tier. Escalating from 4 mg to 8 mg on a 10 mg vial means each 8 mg dose consumes 80% of the vial, leaving an unusable remainder. At that point a larger vial (20 or 30 mg) reconstituted to keep doses on clean marks is more efficient.
- When small doses become imprecise. If you reconstitute strong (say 20 mg/mL) to stretch a vial, a 1 mg dose is only 5 units and a single-unit slip is a 20% error. Re-diluting to a lower concentration restores measurement resolution for small doses.
The general principle: match vial size and water volume to the dose tier you are actually on, not the whole ladder at once. Early low doses favor lower concentrations for precision; later high doses favor larger vials so a single vial covers more than one week. Model both against your schedule with the calculator before opening anything.
Storage: Powder Versus Reconstituted Solution
Storage rules differ sharply before and after water is added.
| State | Condition | Notes |
|---|---|---|
| Lyophilized powder, short term | Room temperature | Acceptable briefly, for example during shipping and immediate handling |
| Lyophilized powder, longer term | Refrigerated (2 to 8 C) | Standard for holding sealed vials before use |
| Lyophilized powder, extended | Frozen | For long-term holding of unopened powder vials |
| Reconstituted solution | 2 to 8 C (refrigerated) | Keep cold at all times once mixed |
| Reconstituted window | 28 to 56 days with BAC water | Preservative-dependent; sterile water does not support this window |
| Reconstituted solution | Never freeze | Freezing damages the peptide and voids the solution |
A few points deserve emphasis:
- Never freeze reconstituted solution. Freeze-thaw cycling degrades the peptide and can render the solution useless. Freezing applies only to unopened powder.
- Protect from light. Keep vials in their box or a dark container. Light exposure accelerates peptide degradation.
- The 28 to 56 day window is a BAC-water window. It assumes benzyl-alcohol-preserved solution kept refrigerated. Without the preservative, the window does not apply.
- Travel handling. Keep reconstituted vials cold in an insulated container with a cold pack, but never let them freeze against the pack, and never leave them at ambient temperature for extended periods. Transport unopened powder cold where possible.
How This Fits the Broader Retatrutide Picture
Reconstitution is upstream of everything else in the research literature. The efficacy numbers that make retatrutide notable, up to 24.2% weight loss at 12 mg over 48 weeks in the Phase 2 obesity trial, an HbA1c reduction up to 2.02% in the Phase 2 type 2 diabetes trial (Lancet, 2023), and liver fat reductions up to roughly 86% in the MASLD substudy, all assume an accurately prepared and measured solution. Sloppy reconstitution introduces a hidden variable that confounds any observation. If you want the efficacy and timeline context, see the results timeline and the benefits and research evidence overview.
For comparison, tirzepatide and semaglutide follow the same reconstitution logic, only the dose ladders and target concentrations differ. The math is identical across the class. New to peptide research handling? Start with the learn hub or test your grasp with the quiz, and log your work in the tracker.
A Note on the "GLP-3" and "Triple G" Nicknames
Grey-market listings frequently market retatrutide as "GLP-3" or "triple G." This is marketing shorthand, not pharmacology. There is no GLP-3 receptor and no GLP-3 hormone. Retatrutide is a triple agonist of three real, distinct receptors: GIP, GLP-1, and glucagon. If a vendor's labeling leans on "GLP-3" as though it were a receptor class, treat that as a signal about the vendor's rigor. For sourcing considerations, see the vendor directory and the where-to-buy guide.
Frequently Asked Questions
Can I use sterile water instead of bacteriostatic water?
Sterile water has no preservative, so a vial reconstituted with it has no protection against microbial growth between draws. Because retatrutide is dosed once weekly and a vial is punctured many times, bacteriostatic water with its 0.9% benzyl alcohol is what supports a multi-week, multi-dose vial. Sterile water is effectively single-use.
How much water should I add to the vial?
There is no single correct volume; it depends on the vial size and the dose you intend to draw. The practical approach is to choose the volume that makes your most-used dose land on a clean multiple of 5 or 10 units on a U-100 syringe. For example, 1 mL into a 10 mg vial gives 10 mg/mL, which puts 1, 4, and 8 mg doses on 10, 40, and 80 units respectively.
Why should I never shake the vial?
Shaking introduces air and foam and applies shear stress that can denature or aggregate the peptide, reducing potency. Injecting the water slowly down the vial wall and then swirling gently gets the powder into solution without that mechanical damage. Full dissolution can take several minutes of patient swirling.
How long does reconstituted retatrutide last?
A bacteriostatic-water-preserved solution kept refrigerated at 2 to 8 C is commonly cited with a 28 to 56 day stability window. That window depends on the benzyl alcohol preservative and cold, dark storage. It does not apply to sterile-water solutions, which lack preservative.
Can I freeze the reconstituted solution to make it last longer?
No. Freezing a reconstituted solution subjects the peptide to freeze-thaw damage and can ruin it. Freezing is only appropriate for unopened lyophilized powder. Once mixed, the solution must stay refrigerated, never frozen.
How do I convert a dose in milligrams to syringe units?
First find the concentration: total vial milligrams divided by milliliters of water added. Then divide your dose by that concentration to get the volume in milliliters, and multiply by 100 to get U-100 syringe units. As a worked case, a 10 mg vial in 2 mL of water is 5 mg/mL, so a 2 mg dose is 0.4 mL, which is 40 units. The calculator does all three steps automatically.
Why does a single 10 mg vial not cover a full 1 to 12 mg escalation?
Because the vial contains a fixed 10 mg of peptide total, regardless of how much water you add. A single 1 mg plus 4 mg plus 8 mg sequence already sums to 13 mg, exceeding the vial. Water changes concentration and dose volume, not the total milligrams available, so higher dose tiers require larger vials or fresh vials.
Key Research Citations
| Title | Journal | Year | What it showed |
|---|---|---|---|
| Triple hormone receptor agonism with retatrutide: a phase 2 trial in obesity | New England Journal of Medicine | 2023 | n=338, 48 weeks; weight change up to -24.2% at 12 mg vs -2.1% placebo; 100% of 8 and 12 mg arms reached at least 5% loss |
| Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: phase 2 trial | Lancet | 2023 | n=281, 36 weeks; HbA1c reduction up to -2.02% at 12 mg vs -0.01% placebo and -1.41% dulaglutide; weight loss up to -16.94% |
| Retatrutide reduces liver fat and MASH markers | New England Journal of Medicine | 2023 | Liver fat content reduced up to ~86% at 24 weeks; about 80% reached normal (under 5%) liver fat |
| Design and characterization of retatrutide: a triple GIP, GLP-1 and glucagon receptor agonist | Molecular Metabolism | 2022 | Established retatrutide as a single-molecule triple receptor agonist; supports once-weekly dosing (terminal half-life ~6 days) |
| Effects of GLP-1 and GIP/GLP-1 receptor agonists on body composition | Nature Reviews Endocrinology | 2023 | Reviewed body composition effects across the incretin agonist class |
Retatrutide remains investigational, with the Phase 3 TRIUMPH program (TRIUMPH-1 through TRIUMPH-4 plus a cardiovascular outcomes study) ongoing. Nothing in this reconstitution guide changes that status. Prepare, measure, and store with the same rigor the underlying research demands, and let the calculator carry the arithmetic.
About the Author
KnowYourPeptide Research Team
KnowYourPeptide Research Team
Content produced by the KnowYourPeptide research and editorial team. All articles are written from peer-reviewed primary literature and reviewed for scientific accuracy by credentialed researchers before publication.
